Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ANI Pharmaceuticals Inc ANIP

Healthcare
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.


NDAQ:ANIP - Post by User

ANI Pharmaceuticals Inc
<< Previous
 Bullboard Posts
User Avatar Image
(237)
•••
Post by whytestockson Nov 08, 2024 4:15pm
29 Views
Post# 36303960

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financ

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financ
NEWS: $ANIP ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 GuidanceGenerated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5% , and record Purified Cortrophin&#xAE; Gel net revenues of $52.6 million, an increase of 76.8% year-over-year Net loss of $(24.2) million and adju...ANIP - ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities